{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T17:28:26Z","timestamp":1788629306709,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Autism Dev Disord"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10803-024-06634-6","type":"journal-article","created":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T06:38:18Z","timestamp":1732343898000},"page":"1658-1670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Parent-Reported Outcome Measures for Individuals with Fragile X Syndrome: Clinically Meaningful Change Thresholds"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6887-9790","authenticated-orcid":false,"given":"Meredith A.","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Berry-Kravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hessl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C.","family":"Shaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejan B.","family":"Budimirovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L.","family":"Reisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Walton-Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,23]]},"reference":[{"key":"6634_CR1","volume-title":"Parenting stress index","author":"RR Abidin","year":"2012","unstructured":"Abidin, R. R. (2012). Parenting stress index (4th ed.). Psychological Assessment Resources, Inc.","edition":"4"},{"issue":"8","key":"6634_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1089\/cap.2019.0177","volume":"30","author":"MG Aman","year":"2020","unstructured":"Aman, M. G., Norris, M., Kaat, A. J., Andrews, H., Choo, T.-H., Chen, C., Wheeler, A., Bann, C., & Erickson, C. (2020). Factor structure of the Aberrant behavior checklist in individuals with Fragile X syndrome: Clarifications and future guidance. Journal of Child and Adolescent Psychopharmacology, 30(8), 512\u2013521.","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"6634_CR3","first-page":"485","volume":"89","author":"MG Aman","year":"1985","unstructured":"Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American journal of mental deficiency., 89, 485.","journal-title":"American journal of mental deficiency."},{"issue":"12","key":"6634_CR4","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/00004583-200312000-00011","volume":"42","author":"LE Arnold","year":"2003","unstructured":"Arnold, L. E., Vitiello, B., McDougle, C., Scahill, L., Shah, B., Gonzalez, N. M., Chuang, S., Davies, M., Hollway, J., & Aman, M. G. (2003). Parent-defined target symptoms respond to risperidone in RUPP autism study: Customer approach to clinical trials. Journal of the American Academy of Child & Adolescent Psychiatry, 42(12), 1443\u20131450.","journal-title":"Journal of the American Academy of Child & Adolescent Psychiatry"},{"issue":"6","key":"6634_CR5","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1001\/archpsyc.1972.01750300078015","volume":"27","author":"LE Arnold","year":"1972","unstructured":"Arnold, L. E., Wender, P. H., McCloskey, K., & Snyder, S. H. (1972). Levoamphetamine and dextroamphetamine: Comparative efficacy in the hyperkinetic syndrome: Assessment by target symptoms. Archives of General Psychiatry, 27(6), 816\u2013822.","journal-title":"Archives of General Psychiatry"},{"issue":"9","key":"6634_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/DBP.0b013e318272dcbc","volume":"33","author":"DB Bailey Jr","year":"2012","unstructured":"Bailey, D. B., Jr., Raspa, M., Bishop, E., Mitra, D., Martin, S., Wheeler, A., & Sacco, P. (2012). Health and economic consequences of fragile X syndrome for caregivers. Journal of Developmental & Behavioral Pediatrics, 33(9), 705\u2013712.","journal-title":"Journal of Developmental & Behavioral Pediatrics"},{"issue":"152","key":"6634_CR110","doi-asserted-by":"publisher","first-page":"152ra127","DOI":"10.1126\/scitranslmed.3004214","volume":"4","author":"EM Berry-Kravis","year":"2012","unstructured":"Berry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K.,  & Hagerman, R. J. (2012). Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized,\ncontrolled, phase 2 trial. Science Translational Medicine, 4(152), 152ra127.","journal-title":"Science Translational Medicine"},{"issue":"1","key":"6634_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s11689-016-9181-6","volume":"9","author":"E Berry-Kravis","year":"2017","unstructured":"Berry-Kravis, E., Hagerman, R., Visootsak, J., Budimirovic, D., Kaufmann, W. E., Cherubini, M., & Carpenter, R. L. (2017). Arbaclofen in fragile X syndrome: Results of phase 3 trials. Journal of Neurodevelopmental Disorders, 9, 1\u201318.","journal-title":"Journal of Neurodevelopmental Disorders"},{"issue":"1","key":"6634_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s11689-022-09466-6","volume":"14","author":"E Berry-Kravis","year":"2022","unstructured":"Berry-Kravis, E., Hagerman, R., Budimirovic, D., Erickson, C., Heussler, H., Tartaglia, N., Cohen, J., Tassone, F., Dobbins, T., & Merikle, E. (2022). A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX). Journal of Neurodevelopmental Disorders, 14(1), 56.","journal-title":"Journal of Neurodevelopmental Disorders"},{"issue":"5","key":"6634_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1089\/cap.2006.16.525","volume":"16","author":"E Berry-Kravis","year":"2006","unstructured":"Berry-Kravis, E., Krause, S. E., Block, S. S., Guter, S., Wuu, J., Leurgans, S., Decle, P., Potanos, K., Cook, E., & Salt, J. (2006). Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: Acontrolled trial. Journal of Child & Adolescent Psychopharmacology, 16(5), 525\u2013540.","journal-title":"Journal of Child & Adolescent Psychopharmacology"},{"key":"6634_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s11689-017-9193-x","volume":"9","author":"DB Budimirovic","year":"2017","unstructured":"Budimirovic, D. B., Berry-Kravis, E., Erickson, C. A., Hall, S. S., Hessl, D., Reiss, A. L., King, M. K., Abbeduto, L., & Kaufmann, W. E. (2017). Updated report on tools to measure outcomes of clinical trials in fragile X syndrome. Journal of Neurodevelopmental Disorders, 9, 1\u201336.","journal-title":"Journal of Neurodevelopmental Disorders"},{"issue":"4","key":"6634_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ajhg.2009.09.007","volume":"85","author":"B Coffee","year":"2009","unstructured":"Coffee, B., Keith, K., Albizua, I., Malone, T., Mowrey, J., Sherman, S. L., & Warren, S. T. (2009). Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. The American Journal of Human Genetics, 85(4), 503\u2013514.","journal-title":"The American Journal of Human Genetics"},{"issue":"4","key":"6634_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3390\/brainsci10040213","volume":"10","author":"MC Coffman","year":"2020","unstructured":"Coffman, M. C., Shaffer, R. C., Schmitt, L. M., Dominick, K. C., Pedapati, E., Wang, A., Berry-Kravis, E., Tartaglia, N., & Erickson, C. A. (2020). Examination of correlates to health-related quality of life in individuals with fragile X syndrome. Brain Sciences, 10(4), 213.","journal-title":"Brain Sciences"},{"key":"6634_CR12","unstructured":"FDA. (2019). United States Food and Drug Administration. Incorporating clinical outcome assessments into endpoints for regulatory decision-making. https:\/\/www.fda.gov\/media\/132505\/download"},{"key":"6634_CR13","volume-title":"ECDEU assessment manual for psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy, W. (1976). ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service."},{"issue":"1","key":"6634_CR14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1542\/peds.2008-0317","volume":"123","author":"RJ Hagerman","year":"2009","unstructured":"Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., & Visootsak, J. (2009). Advances in the treatment of fragile X syndrome. Pediatrics, 123(1), 378\u2013390.","journal-title":"Pediatrics"},{"issue":"20","key":"6634_CR15","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1001\/jama.2008.684","volume":"300","author":"RJ Hagerman","year":"2008","unstructured":"Hagerman, R. J., & Hagerman, P. J. (2008). Testing for fragile X gene mutations throughout the life span. JAMA, 300(20), 2419\u20132421.","journal-title":"JAMA"},{"key":"6634_CR16","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.jad.2020.11.066","volume":"281","author":"S Hudgens","year":"2021","unstructured":"Hudgens, S., Floden, L., Blackowicz, M., Jamieson, C., Popova, V., Fedgchin, M., Drevets, W. C., Cooper, K., Lane, R., & Singh, J. (2021). Meaningful change in depression symptoms assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery\u2013\u00c5sberg Depression Rating Scale (MADRS) among patients with treatment resistant depression in two, randomized, double-blind, active-controlled trials of esketamine nasal spray combined with a new oral antidepressant. Journal of Affective Disorders, 281, 767\u2013775.","journal-title":"Journal of Affective Disorders"},{"issue":"5","key":"6634_CR17","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJMoa013171","volume":"347","author":"JT McCracken","year":"2002","unstructured":"McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., & Hollway, J. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314\u2013321.","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"6634_CR18","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.3390\/ijms23041935","volume":"23","author":"DD Protic","year":"2022","unstructured":"Protic, D. D., Aishworiya, R., Salcedo-Arellano, M. J., Tang, S. J., Milisavljevic, J., Mitrovic, F., Hagerman, R. J., & Budimirovic, D. B. (2022). Fragile X syndrome: From molecular aspect to clinical treatment. International Journal of Molecular Sciences, 23(4), 1935.","journal-title":"International Journal of Molecular Sciences"},{"key":"6634_CR19","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s10803-011-1370-2","volume":"42","author":"SM Sansone","year":"2012","unstructured":"Sansone, S. M., Widaman, K. F., Hall, S. S., Reiss, A. L., Lightbody, A., Kaufmann, W. E., Berry-Kravis, E., Lachiewicz, A., Brown, E. C., & Hessl, D. (2012). Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment. Journal of Autism and Developmental Disorders, 42, 1377\u20131392.","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"6634_CR20","volume-title":"Vineland II: Vineland adaptive behavior scales","author":"SS Sparrow","year":"2005","unstructured":"Sparrow, S. S., Balla, D. A., Cicchetti, D. V., & Doll, E. A. (2005). Vineland II: Vineland adaptive behavior scales. American Guidance Service."},{"issue":"2","key":"6634_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/brainsci9020018","volume":"9","author":"JD Weber","year":"2019","unstructured":"Weber, J. D., Smith, E., Berry-Kravis, E., Cadavid, D., Hessl, D., & Erickson, C. (2019). Voice of people with fragile X syndrome and their families: Reports from a survey on treatment priorities. Brain Sciences, 9(2), 18.","journal-title":"Brain Sciences"},{"issue":"1","key":"6634_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/ajmg.a.36232","volume":"164","author":"A Wheeler","year":"2014","unstructured":"Wheeler, A., Raspa, M., Bann, C., Bishop, E., Hessl, D., Sacco, P., & Bailey, D. B., Jr. (2014). Anxiety, attention problems, hyperactivity, and the aberrant behavior checklist in fragile X syndrome. American Journal of Medical Genetics Part A, 164(1), 141\u2013155.","journal-title":"American Journal of Medical Genetics Part A"},{"issue":"5","key":"6634_CR23","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/aur.213","volume":"4","author":"A Zaidman-Zait","year":"2011","unstructured":"Zaidman-Zait, A., Mirenda, P., Zumbo, B. D., Georgiades, S., Szatmari, P., Bryson, S., Fombonne, E., Roberts, W., Smith, I., & Vaillancourt, T. (2011). Factor analysis of the parenting stress index-short form with parents of young children with autism spectrum disorders. Autism Research, 4(5), 336\u2013346.","journal-title":"Autism Research"}],"container-title":["Journal of Autism and Developmental Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10803-024-06634-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10803-024-06634-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10803-024-06634-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:37:41Z","timestamp":1773398261000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10803-024-06634-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,23]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["6634"],"URL":"https:\/\/doi.org\/10.1007\/s10803-024-06634-6","relation":{},"ISSN":["0162-3257","1573-3432"],"issn-type":[{"value":"0162-3257","type":"print"},{"value":"1573-3432","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,23]]},"assertion":[{"value":"29 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lauren Schmitt is a consultant for Confluence Pharmaceuticals, Stalicla, and Scioto Biosciences with no direct conflicts to the content presented. Elizabeth Berry-Kravis has received funding from Acadia, Alcobra, AMO, Asuragen, Avexis, Biogen, BioMarin, Cydan, Engrail, Erydel, Fulcrum, GeneTx, GW, Healx, Ionis, Jaguar, Kisbee, Lumos, Marinus, Moment Biosciences, Neuren, Neurogene, Neurotrope, Novartis, Orphazyme\/Kempharm\/Zevra, Ovid, PTC Therapeutics, Retrophin, Roche, Seaside Therapeutics, Taysha, Tetra, Ultragenyx, Yamo, Zynerba, and Vtesse\/Sucampo\/Mallinckrodt Pharmaceuticals, to consult on trial design or run clinical or lab validation trials in genetic neurodevelopmental or neurodegenerative disorders, all of which is directed to RUMC in support of rare disease programs; Dr Berry-Kravis receives no personal funds and RUMC has no relevant financial interest in any of the commercial entities listed. David Hessl has received funding from the following, all of which are directed to the UC Davis, in support of fragile X treatment programs, and he receives no personal funds and has no relevant financial interest in any of the commercial entities listed: Autifony, Ovid, Tetra\/Shionogi, Healx, and Zynerba pharmaceutical companies to consult on outcome measures and clinical trial design. Randall Carpenter is the founder of Seaside Therapeutics, the company that performed the clinical trials.\u00a0He is also the founder of Allos Pharma, the company that is currently developing arbaclofen for fragile X syndrome. Over the past 24\u00a0months, Dejan B. Budimirovic, MD, has received funding from Zynerba Pharmaceuticals (ZYN2-CL-017, ZYN2-CL-033) and Tetra Discovery Partners, Inc. (BPN14770-CNS-204, BPN14770-CNS-301, BPN14770-CNS-302) as an investigator on the listed five clinical trials in individuals with fragile X syndrome (FXS). He has also received funding from CDC (RFA-DD-21\u2013002). All the above funding has been directed to the Kennedy Krieger Institute\/the Johns Hopkins Medical Institutions, meaning that Dr. Budimirovic receives no personal funds, and the Institute has no relevant financial interest in any of the commercial entities listed. Paul Wang is an employee of Clinical Research Associates, LLC, a non-profit and formally worked for Seaside Therapeutics. Karen-Walton Bowen has previously worked at Seaside Therapeutics and currently works at Clinical Research Associates, LLC. Craig Erickson is a consultant to Spinogenix, Stalicla, and Scioto Biosciences with no direct conflicts to the content presented.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}